A B S T R A C T A radioimmunoassay for fibrinopeptide A (FPA) has been developed. This assay uses rabbit antibodies induced by injection of native FPA-human serum albumin conjugates and 1"I introduced into tyrosine-FPA synthesized in our laboratory. Plasma FPA is separated from fibrinogen by TCA extraction. The assay is capable of detecting as little as 50 pg/ml of FPA.
INTRODUCTION
Thrombin is a proteolytic enzyme which acts on the Aa and BPi chains of fibrinogen to release 2 mol each of fibrinopeptide A (FPA)' and fibrinopeptide B (FPB) and 1 mol of fibrin monomer (1) . The release of FPA is more rapid than the release of FPB, and clotting occurs as soon as FPA has been cleaved from fibrinogen (2, 3) . Thus the determination of FPA release is a direct measure of the conversion of fibrinogen to fibrin. Nossel et al. (4, 5) , Gerrits et al. (6) , and Budzynski et al. (7) have recently developed radioimmunoassays for the detection of FPA. We are reporting the independent development of such an assay which uses an improved method for separating FPA from antigenically related material in plasma. This assay has been used to determine the level of FPA in normal donors, patients with disseminated intravascular coagulation (DIC), and patients with systemic lupus erythematosus (SLE) . In the latter group, close correlation was observed between plasma FPA levels and other parameters of disease activity.
METHODS
Preparation of immunogen and antiserum. Human fibrinogen was prepared from fresh plasma by cold ethanol fractionation, followed by DEAE-cellulose chromatography according to the method of Laki (8) . Fibrinogen (l-g portions) was clotted by the addition of 100 U of bovine thrombin (Parke Davis & Co., Detroit, Mich.). After 2 h, the supernate and the first wash of the .homogenized clot were combined and concentrated by lyophilization. The peptide fraction was isolated by chromatography on Sephadex G-25 (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) in 0.1 'Abbreviations used in this paper: FPA, fibrinopeptide A; FPB, fibrinopeptide B; GuHCI, guanidine hydrochloride; DIC, disseminated intravascular coagulation; SLE, systemic lupus erythematosus; TCA, trichloroacetic acid. M NH4HCO3, and was further purified by preparative highvoltage electrophoresis on Whatman 3 MM paper at pH 6.5 in pyridine: acetic acid: water (25: 1: 225) at 50 V/cm. Several ninhydrin-positive bands were found. After elution of the bands, the fraction having an amino acid oomposition corresponding to that of FPA was used for synth,esis of immunogen. Purified FPA (11 mg) and human serum albumin (22 mg) in water (1 ml) were coupled by reaction with 1-cyclohexyl-3-(2-morpholinoethyl) -carbodiimide (200 mg) for 1 h at room temperature. Reagents were removed by threefold dialysis in 2 liters of water. The immunogen was diluted with water to a final concentration of 2 mg FPA/ml of water. This solution was emulsified with an equal volume of Freund's adjuvant (Difco Laboratories, Detroit, Mich.) plus added tubercle bacilli (10 mg/ml). The emulsion was injected into the toe pads or into multiple intradermal sites of New Zealand white rabbits. Injections were repeated at intervals of 2-4 wk., a total of two to six injections were administered.
Synthesis of peptides. Tyrosylalanylaspartylserylglycylglutamylglycylaspartylphenylalanylleucylalanylglutamylglycylglycylglycylvalylarginine (Tyr-FPA) and alanylaspartylserylglycylglutamylglycylaspartylphenylalanylleucylalanylglutamylglycylglycylglycylvalylarginine (FPA) were synthesized by using the solid-phase method of Merrifield (9, 10) . BocArg (Tos) was esterified to Biobeads SX .1 (Bio-Rad Laboratories, Richmond, Calif.), 0.69 meq Cl/g, by heating equimolar amounts of material under reflux conditions in ethanol containing 0.9 mol eq of triethylamine. After a standard purification procedure (10) , amino acid analysis showed 80.7 ,tmol arginine/g support (13%o). Synthesis of the peptides was completed by using the cycle of synthetic operations described previously (11) . Amino acids were coupled using the Nc-tert-butoxycarbonyl derivatives (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif). Sidechain protection was: arginine, N0-tosyl, tyrosine, O-benzyl; serine, O-benzyl; aspartic acid, p-benzyl ester, and glutamic acid, -y-benzyl ester. The molar ratio of added amino acid to the growing peptide was 3.5: 1. On completion of the synthetic operations, 1.5 g of protected peptidyl resin was treated with HF-10% anisole (vol/vol) for 90 min at 0°C. After evaporation, the residue was extracted with 1 M acetic acid, filtered, and lyophilized to yield 135 pmol of product.
In separate purifications, portions of the products (40 /Amol) were dissolved in 6 ml of 1 M acetic acid and frac- to new polypropylene tubes containing 1.0 ml of anticoagulation solution that contained 38 mg trisodium citrate, 0.5 mg soy bean trypsin inhibitor, 1 mmol e-aminocaproic acid, and 10 Mmol Na2EDTA. The samples were centrifuged for 15 min at 2,000 g in the cold, and the plasma was transferred with a disposable polyethylene pipet to another new polypropylene tube and stored at -20'C until tested. A 2-ml sample of plasma was precipitated with an equal volume of ice-cold 20%o TCA in 16 x 100-mm glass tubes in an ice bath. Samples were centrifuged immediately, and the supernates were decanted into 16 X 100-mm test tubes. The supernates were extracted three times with 3 ml of ether using a Vortex mixer to combine the fluid phases and centrifugation to separate them. After three extractions, the pH of the aqueous phase, which contains the FPA, was above 3. A drop of mixed methyl red indicator (15) was added, and the samples were titrated to neutrality by adding 10 N NaOH with a syringe microburet equipped with a finely pulled glass tip. Neutralization of the extract of a 2-ml plasma sample required [25] [26] [27] [28] [29] [30] /Al of 10 N NaOH, and resulted in dilution of the sample by about 0.01 vol or less. The samples were heated to 500C in a water bath, then removed from the bath and placed under water aspirator vacuum until they began to boil. The vacuum was quickly released and the evacuation process repeated five times. Incomplete removal of ether results in falsely elevated levels in the calculated plasma concentration of FPA.
Assays for DNA-binding activity and C3 concentration.
DNA-binding activity was measured by the Millipore filter technique (16) . KB cell DNA labeled with "=I (ElectroNucleonics Laboratories, Bethesda, Md.) and nonradioactive calf thymus DNA (Sigma Chemical Co., St. Louis, Mo.) were combined in 0.15 M Tris buffer pH 7.5 at a final concentration of 1.0 pzg/ml (-2 X 10' cpm/iug). In the assay 0.1 ,ug 'I-DNA and 25 ul of test serum were incubated at 37'C for 30 min and subsequently filtered through a HAWP Millipore filter (Millipore Corp., Bedford, Mass.). After washing the filter, the radioactivity retained on the filter was measured in a crystal scintillation spectrometer; binding activity was expressed as a percentage of the total radioactivity added to serum. For normal sera the mean percentage of binding plus 2 SDS was 30%o.
The serum concentration of C3 was estimated by using commercial immunodiffusion plates (Behring Diagnostics, Somerville, N. J.).
Selection of subjects. Plasma samples were obtained from 20 healthy donors of both sexes whose ages ranged from the 2nd-5th decades. Five patients with DIC who fulfilled previously published criteria for the diagnosis of this disorder (17) were studied; in four patients DIC was attributed to sepsis and in one patient was of unknown etiology. Patients with SLE (28 females, 1 male) were selected from the inpatient and outpatient services of the Massachusetts General Hospital and the Clinical Center of the National Institutes of Health. These patients met the preliminary criteria of the American Rheumatism Association for the diagnosis of SLE (18) . The following criteria led to exclusion from the study: recent surgery, hemodialysis, major infection, presence of indwelling venous or arterial catheters, or platelet counts less than 100,000. There were 29 patients with SLE available for study. These patients were categorized as having active SLE if, in the absence of other causes, one or more of the following conditions were present: alopecia, arthritis, active skin lesions, pleuritis, pericarditis, peritonitis, hepatitis, pneumonitis, myocarditis, or unexplained fever. Lupus nephritis was considered to be present in an active form in patients with one or more of the following conditions: red cell casts present in freshly voided urine, granular casts associated with hematuria equal to or greater than 20 erythrocytes/ high power field, pyuria equal to or greater than 20 leukocytes/high power field and not accounted for by infection, or proteinuria equal to or greater than 1 g/24 h.
Statistical treatment. Data from control and patient groups were analyzed by the chi-square test with Yates' correction.
RESULTS
Characterization of antibody. 10 rabbits were immunized with FPA-human serum albumin conjugates; of these, two produced antibodies with sufficiently high binding affinities and titers to be useful in the assay. At high concentration, antisera R10 and R17 bound up to 90% of a tracer dose of "5I-Tyr-FPA (4 pg; 10,000 cpm). A 1:2,000 dilution of antiserum R10 bound 37% of the tracer dose; of this amount, 50% was displaced by 22 ng of unlabeled FPA (Fig. 1) . A 1: 5,000 dilution of antiserum R17 bound 47% of the tracer dose; of this amount, 50% was displaced by 0.5 ng of FPA. Synthetic FPA, natural FPA, and fibrinogen containing equivalent amounts of FPA were equipotent in the displacement of bound 'I-Tyr-FPA from antiserum R17. In contrast, 50% displacement of the label from antiserum R10 required a 6.5-fold molar excess of FPA equivalents as fibrinogen, in comparison to synthetic FPA (Fig. 1) . The binding of FPB to antiserum R17 was much less than that of FPA; 500 ng of FPB (mol wt, 1,535) displaced a tracer dose of 'I-Tyr-FPA to the same extent as 0.1 ng of FPA (mol wt, 1,537).
Despite the increased cross-reactivity with fibrinogen of antiserum R17 compared to antiserum R10, R17 was routinely used at a dilution of 1:5,000 because of the greater sensitivity of the assay performed under this condition.
Reproducibility and accuracy of method. 20 replicates of the same plasma sample from a normal donor were processed as described. The mean FPA concentration was 0.88 ng/ml, with an SD of 0.31 ng/ml. In another experiment, varying quantities of FPA were added to replicate plasma samples, which were then processed and assayed. The results, shown in Table I (Table III) . The results show that in the presence of EDTA, FPA immunoreactivity increases slowly. In contrast, in the absence of EDTA, there is a significant increase in FPA immunoreactivity after 60 min of digestion time. Gel electrophoresis of the fibrinogen solutions digested in the presence of EDTA showed the appearance of X and Y fragments during the 30-to 240-min incubation period; D and E fragments did not appear until 24 h of digestion time, corresponding to a stage 3 digest (7). In the absence of EDTA, 60 min of digestion results in a stage 3 digest (7). These experiments indicate that FPA immunoreactivity is not markedly increased in fibrinogen solutions until extensive plasmin digestion has occurred, and that digestion occurs at a slow rate in plasma.
In a third experiment, 25 ml of plasma from a patient with DIC was processed in the conventional manner, except that the extracted material was lyophilized, desalted on Sephadex G-10, relyophilized, and the dried residue dissolved in 3 ml of 6 M guanidine HCl (GuHCl). The solution was applied to a 1.2 X 100-cm column of Sephadex in 6 M GuHCl. The (Fig. 2) . The elution profile of synthetic FPA (not shown in Fig. 2 ) was also determined in a separate experiment with the same column and was identical with that of native FPA. The elution volume of insulin B chain (30 amino acid residues) was clearly differentiated from that of FPA (16 amino acid residues). This experiment demonstrates that there are no detectable immunoreactive substances differing in size from native FPA in plasma from a patient with a diffusely activated coagulation mechanism. The smallest crossreacting peptide expected is the 1-23Aa plasmin digestion product, which would be eluted in the position indicated by the arrow in Fig. 2 .
FPA in normal donors. The concentration of FPA in the blood of 20 healthy donors was found to range from 0.6 to 1.9 ng/ml with a mean of 0.9 ng/ml and an SD of 0.3 ng/ml. (17, 19) . To determine whether patients with DIC also manifested elevated levels of FPA, plasma from five patients with this disorder was tested (Table V) . FPA values ranged from 13 to 346 ng/ml. None of these patients had been treated with heparin before sampling. Methods (Table VI) . FPA values shown are those obtained on the first sample from each patient. 13 patients were in remission; of these, 4 had been free of renal disease while 9 previously had nephritis. 15 FPA was measured in several plasma samples from one patient with SLE whose active disease was rapidly controlled by corticosteroid therapy (Fig. 3) . The plasma FPA concentration decreased rapidly after treatment was begun and it paralleled clinical improvement. During convalescence a rise in FPA concentration was observed; this change was followed by recurrence of a skin rash. The FPA concentration again declined with subsidence of these lesions. During this entire episode, the DNA-binding activity gradually declined; no increase in binding activity in relationship to the skin rash was observed.
The concentration of C3 in serum from 17 patients was compared with the concentration of FPA determined on a corresponding plasma sample (Fig. 4) ; in the 12 other patients with SLE, simultaneous C3 and FPA values were not available. 8 ng/ml), and moderately elevated in 2 patients (3.1 and 4.8 ng/ml). With one exception, patients with a decreased concentration of C3 had elevated levels of FPA. In 12 patients with SLE, simultaneous creatinine and FPA levels were available for comparison. Within this group a single patient had an elevated serum creatinine of 2.2 mg/dl, but a near normal FPA level of 1.8 ng/ml. Four patients had simultaneous elevations of FPA and creatinine. The remaining 7 patients had normal creatinine levels but FPA values ranged from 0.7 to 11.0 ng/ml. Among these 12 patients there was no significant relationship (x2 = 0; P > 0.05) between the serum creatinine and the measured FPA level.
DISCUSSION
A major requirement in the development of a radioimmunoassay for FPA is for discrimination between free FPA and the FPA sequence of fibrinogen and certain fragments of fibrinogen. One approach is the production of antisera that are capable of recognizing determinants present only on free FPA. In the present experiments, immunogen was prepared by coupling purified native FPA to human serum albumin with carbodiimide. The antisera produced in response to this immunogen, however, failed to distinguish between free FPA and the FPA sequence of native fibrinogen (R17), or it showed only moderate preference for the free FPA (Table I) . Nossel et al. (5) have previously reported a different separation technique based on ethanol precipitation of proteins followed by dialysis of the supernate to recover FPA. While the two methods have not been compared directly, TCA precipitation seems more rapid and allows a larger number of samples to be processed by one technician.
Three experiments were performed to determine whether any immunoreactive substances other than FPA might be present in TCA extracts of blood plasma. In the first of these (Table II) , measured values of FPA conformed with calculated values in dilutions of a single pool of TCA extract of plasma. Immunoreactive substances containing the FPA sequence would be expected to show binding curves identical with those of native FPA, and this prediction holds for native fibrinogen (Fig. 1) . Nonspecifically cross-reacting substances, however, are very unlikely to have the same binding properties as the native FPA determinant, and therefore the binding curve would be altered. The accuracy with which FPA concentrations were predicted in the diluted extract therefore demonstrates that cross-reacting substances were not isolated in any significant quantities during TCA extraction of FPA from plasma.
In the second experiment (Table III) it was shown that extensive plasmin digestion of fibrinogen is required before FPA immunoreactivity increases in TCA extracts of fibrinogen solutions. The results of these experiments corroborate those of Budzynski et al. (7) who also noted that increase of FPA immunoreactivity was associated with the appearance of plasmin fragments of the D and E type. Based on molecular size, fragments D and E would be separated from FPA by either the TCA fractionation method here described or by the ultrafiltration system used by Budzynski et al. (7) . The increase in immunoreactivity, therefore, is not due to the presence of fragment E in the extracts, nor is it due to increase in FPA, since plasmin does not cleave the 16-17 peptide bond of the Aa chain, which contains the FPA sequence (20) . Low molecular weight fragments begin to appear only after the Aa chain has been extensively degraded, as signaled by the appearance of D and E fragments. A small peptide, the 1-23 Aa fragment, is produced late in plasmin digestion of fibrinogen, but at a low generation rate (20) . The third experiment indicates that low molecular weight, plasmin-derived fragments containing FPA were not produced at a sufficient rate to interfere with the measurement of FPA. Gel-filtration chromatography under dissociating conditions was performed with a TCA extract of plasma from a patient with DIC (Fig. 2) . In DIC appreciable amounts of plasmin-produced fragments cross-reactive with FPA might appear in plasma as a consequence of activation of the clotting and fibrinolysin systems. Of chief concern was the possibility that the 1-23 Aa-chain fragment produced by the action of plasmin on fibrinogen (20) might be present in significant amounts and extracted from such samples together with FPA. Gel filtration of such a plasma TCA extract showed a single peak of FPA activity corresponding to the elution position of native FPA (Fig. 2) . Insulin B chain (30 amino acid residues) was readily resolved from FPA on this column. The elution position of each peptide is a function of its hydrodynamic size. In the strong dissociating solvent used in elution, hydrodynamic size is a function of the number of residues in the peptide chain (21) . The hydrodynamic size of the 1-23 Aa-chain fragment was calculated from data in reference 21. Based on these calculations, the fragment would appear at the position indicated by the arrow in Fig. 2 ; little immunoreactive material was detected at this position. Thus it appears that no significant crossreacting substance was detectable in the plasma extract. Nossel et al. (5) also concluded that the immunoreactive substance in the plasma of patients with DIC was FPA.
The FPA assay was applied to an examination of the role of the clotting system in SLE. Fibrin deposition in the renal glomerulus is believed to be important in the pathogenesis of lupus nephritis (22) (23) (24) . The deposition of antigen-antibody-complement complexes in the glomerulus may result in localized intravascular coagulation with consequent fibrin deposition (25) . Evidence for the occurrence of low-level DIC in SLE has been provided by studies based chiefly on the detection of fibrinogen/fibrin degradation products in serum (22) (23) (24) . Since production of fibrinogen/fibrin degradation products generally depends on clotting followed by fibrinolysis, detection provides only an indirect estimate of clotting. Some investigators have also reported abnormal coagulation studies (23) , while others have failed to find consistent changes (26) . Since the FPA assay measures the initial alteration of the fibrinogen molecule in the clotting process and does not depend on depletion of clotting factors or the secondary release of fibrin degradation products, its application to studies of patients with SLE may directly define the rate of intravascular coagulation.
In the present study, FPA values above the normal range were detected in plasma from 22 of 29 patients with SLE. These patients were classified in four categories on the basis of the activity of their disease and the presence or absence of renal involvement (Table   VI) . Patients with inactive disease tended to have plasma FPA values within the normal range, although in group II, four patients with a history of renal involvement had clearly elevated FPA levels. Patients with active disease without renal involvement (group III) had a mean FPA level of 4.5 ng/ml. The major sites of involvement in these patients included the joints, skin, serosal surfaces, lung, and liver. There was no consistent relationship between any one manifestation of disease activity and a unique plasma FPA value. Patients with active renal disease (group IV) had the highest FPA levels; a mean concentration of 10.2 ng/ml was found in this group. Four of the seven patients in group IV had elevated levels of serum creatinine. It is possible that renal impairment contributed to the high levels of FPA observed in these patients. Stiehm and Trygstad (20) , as well as others (27) , have noted that patients with uremia invariably had high levels of fibrinogen/fibrin degradation products. It should be noted, however, that among the present group, elevated levels of FPA were seen in the absence of uremia in patients with active SLE. Thus, factors other than impaired renal clearance can lead to elevated FPA levels in patients with active SLE.
The capacity of serum to bind DNA and the concentration of serum complement reflect disease activity in SLE. An increase in DNA binding, a fall in concentration of C3, or both, often heralds or accompanies an increase in disease activity (28, 29) . In this study, a positive correlation was found between levels of plasma FPA and DNA-binding activity, and an inverse correlation was found between plasma FPA and concentration of C3 (Fig. 4) . Since both enhanced DNAbinding activity and complement depletion are closely related to the pathogenesis of the renal lesions in SLE, the generation of FPA may also be related to this process. Additionally, FPA release may occur at other sites of conversion of fibrinogen to fibrin in diverse, inflamed organs, such as the skin (30) .
While it seems likely that the FPA measured in this study results from the action of thrombin on fibrinogen, other proteolytic enzymes may also be responsible. Plow and Edgington (31) have recently described a leukocyte protease that cleaves fibrinogen at physiologic pH. If FPA were one of the products of this enzyme, then a cell type that is closely related to inflammation might account for the relationship between disease activity and FPA generation that is observed in patients with SLE.
Finally it must be considered that the increased FPA levels observed in SLE may reflect the increased metabolic turnover of fibrinogen. Patients with SLE tend Fibrinopeptide A in Systemic Lupus Erythematosus to have elevated plasma fibrinogen (32) . Few turnover studies in patients with SLE have been reported (33) . In rheumatoid arthritis, greatly increased catabolic and synthetic rates were found; the increased synthetic rate was roughly proportional to the severity of the disease process (34) . Direct comparisons between FPA levels and fibrinogen turnover will be required to test the possibility that elevated FPA in SLE reflects enhanced metabolism of fibrinogen.
